SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials

30-Jul-2010 - Netherlands

SynCo Bio Partners announced an extension of its collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis’ lead product VRS-859 (exenatide-XTEN).

Under the extended agreement, SynCo will scale-up a second manufacturing process on behalf of Versartis, this time in preparation for the GMP manufacture of VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency. As with the VRS-859 program, SynCo will also provide fill and finish services for the manufacture, testing and release of formulated Drug Product vials. SynCo completed process development and optimization, scale-up and GMP manufacture of VRS-859 for Phase 1 clinical studies earlier this year.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances